This experimental Alzheimer’s disease drug seemed promising — before the latest results left many unsure

An experimental drug from drugmakers Biogen and Eisai emerged this summer with the potential to do what no other medication has been able to: slow the development of Alzheimer’s disease, a progressive and devastating disease marked by cognitive decline.

But a major question — whether differences in genetic risk for the disease explain away the late July results — has hung over the drug, called BAN2401.

With new study results, presented by the two companies early Thursday at a European conference, the uncertainty lingers on, even as it has become more complicated.

>>> Original Source <<<